Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661553 | 1.00 | OPRM1 (0.34) | OPRM1OPRD1OPRK1SIGMAR1KDM4E | |
| SCHEMBL6653869 | 0.86 | SIGMAR1 (0.42) | OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL6653871 | 0.86 | SIGMAR1 (0.42) | OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL6654080 | 0.86 | OPRM1 (0.41) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6654085 | 0.86 | OPRM1 (0.41) | OPRM1OPRD1OPRK1 | |
| SCHEMBL5756887 | 0.82 | OPRM1 (0.43) | OPRM1OPRD1OPRK1SIGMAR1KDM4E | |
| SCHEMBL7644676 | 0.81 | OPRM1 (0.42) | OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL7644674 | 0.81 | OPRM1 (0.42) | OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL6655772 | 0.79 | OPRM1 (0.42) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6655769 | 0.79 | OPRM1 (0.42) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | OPRM1 409/4885OPRD1 102/4885OPRK1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.